Entero Therapeutics (NASDAQ:ENTO) Trading 0.5% Higher – Should You Buy?

Entero Therapeutics, Inc. (NASDAQ:ENTO)’s share price traded up 0.5% during trading on Monday . The stock traded as high as $3.88 and last traded at $3.79. 13,569 shares were traded during mid-day trading, a decline of 86% from the average session volume of 99,541 shares. The stock had previously closed at $3.77.

Analyst Ratings Changes

Several research firms recently weighed in on ENTO. Wall Street Zen upgraded Entero Therapeutics to a “hold” rating in a research report on Friday, October 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Entero Therapeutics in a research report on Tuesday, October 14th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has an average rating of “Sell”.

Entero Therapeutics Stock Down 19.8%

The firm has a 50 day moving average price of $4.30 and a two-hundred day moving average price of $2.51.

Entero Therapeutics (NASDAQ:ENTO) last posted its quarterly earnings results on Wednesday, November 19th. The company reported ($0.75) EPS for the quarter.

Institutional Trading of Entero Therapeutics

An institutional investor recently bought a new position in Entero Therapeutics stock. Virtu Financial LLC acquired a new position in shares of Entero Therapeutics, Inc. (NASDAQ:ENTO) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 11,829 shares of the company’s stock, valued at approximately $59,000. Virtu Financial LLC owned approximately 0.74% of Entero Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 12.30% of the company’s stock.

Entero Therapeutics Company Profile

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.